Latest News
-

2015 Huntington's Disease Therapeutics Conference: Day 3
Day 3 of updates from the annual HD Therapeutics Conference in Palm Springs
-

2015 Huntington's Disease Therapeutics Conference: Day 2
Day 2 of updates from the annual HD Therapeutics Conference in Palm Springs
-

2015 Huntington's Disease Therapeutics Conference: Day 1
Day 1 of updates from the annual HD Therapeutics Conference in Palm Springs
-

Unlocking the Potential of Antibodies as a Therapy for Huntington’s Disease
Antibodies are known for their role in immunity, but researchers repurpose them in many ways. Can they be used in HD?
-

Drug Improves Huntington’s Symptoms in Mice – and Their Offspring
HD drug changes DNA folding across generations
-

mTORC1 tips the scales in Huntington’s disease mice
Weighing the scales on mTORC1: A possible new target for HD therapeutics?
-

Can this synthetic oil help feed the brain in Huntington's disease?
A new study shows a synthetic oil called triheptanoin changes how HD brains use energy. But will it help HD?
-

Positive results announced for re-worked tetrabenazine drug in Huntington's disease
Modified 'heavy hydrogen' form of tetrabenazine appears safe and effective for chorea in Huntington's disease
-

Turning skin cells into brain cells: a Huntington's disease research breakthrough?
Scientists can now change human skin cells into working neurons, like the ones that are most affected in HD.
-

Huntington's disease clinical trial announcement: huntingtin-lowering drug to enter Phase I trial in 2015
A clinical trial for an exciting therapy against HD is planned for 2015. The first step is to make sure it is safe.
HDBuzz Trial Tracker
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
REGEN4HD, Phase 1 stem cell implantation study commences
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Updates from the ongoing placebo-controlled Phase 2/3 FALCON-HD trial
Previously featured
-
June 2026: This Month in Huntington’s Disease Research
-
Precision Pruning with PROTACs: Selective Targeting of Toxic Huntingtin
-
Your DNA Shouldn’t Cost You Your Insurance: What HD Families Need to Know
-
The Other Shoe Drops: uniQure Shares Plans To Submit Licensing Application With The FDA for AMT-130
-
First participant dosed in pioneering neural stem cell trial for Huntington’s disease
Follow HDBuzz
Sign up to our monthly email summary by entering your email address on our mailing list page.
Suggest an article
Is there something you want us to write about? Tell us about it here. We consider all suggestions but can’t promise to write content about any particular suggestion.
